These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 14517187)

  • 21. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
    Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
    Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Thomas AL; Trarbach T; Bartel C; Laurent D; Henry A; Poethig M; Wang J; Masson E; Steward W; Vanhoefer U; Wiedenmann B
    Ann Oncol; 2007 Apr; 18(4):782-8. PubMed ID: 17218488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
    Van Cutsem E; Bajetta E; Valle J; Köhne CH; Hecht JR; Moore M; Germond C; Berg W; Chen BL; Jalava T; Lebwohl D; Meinhardt G; Laurent D; Lin E
    J Clin Oncol; 2011 May; 29(15):2004-10. PubMed ID: 21464401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
    Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
    Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
    van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
    NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
    O'Reilly T; Lane HA; Wood JM; Schnell C; Littlewood-Evans A; Brueggen J; McSheehy PM
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):193-200. PubMed ID: 20512579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
    Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
    Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
    Posey JA; Ng TC; Yang B; Khazaeli MB; Carpenter MD; Fox F; Needle M; Waksal H; LoBuglio AF
    Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
    Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS; Herbst RS; Liu G; Park JW; Kies MS; Steinfeldt HM; Pithavala YK; Reich SD; Freddo JL; Wilding G
    J Clin Oncol; 2005 Aug; 23(24):5474-83. PubMed ID: 16027439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble markers for the detection of hypoxia under antiangiogenic treatment.
    Drevs J
    Anticancer Res; 2003; 23(2A):1159-61. PubMed ID: 12820365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI.
    Cantwell CP; Setty BN; Holalkere N; Sahani DV; Fischman AJ; Blake MA
    J Comput Assist Tomogr; 2008; 32(5):738-44. PubMed ID: 18830103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis.
    Atkin G; Taylor NJ; Daley FM; Stirling JJ; Richman P; Glynne-Jones R; d'Arcy JA; Collins DJ; Padhani AR
    Br J Surg; 2006 Aug; 93(8):992-1000. PubMed ID: 16673354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer.
    Zahra MA; Tan LT; Priest AN; Graves MJ; Arends M; Crawford RA; Brenton JD; Lomas DJ; Sala E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):766-73. PubMed ID: 19019563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer.
    George ML; Dzik-Jurasz AS; Padhani AR; Brown G; Tait DM; Eccles SA; Swift RI
    Br J Surg; 2001 Dec; 88(12):1628-36. PubMed ID: 11736977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.